Taking all this together in conjunction with a recent finding suggesting that the inhibition of PARP1 can help curb inflammation-associated NSCLC development, specifically lung AC [23], it is likely that PARP1 may have a role in lung carcinogenesis and warrants rigorous characterization and understanding the role of PARP1 in promoting NSCLC subtype development. The gene discussed is PARP1; the disease is non-small cell lung carcinoma.